GCI Virtual Summit Thought Leader – Dr. David Feifel, Kadima Neuropsychiatry Institute

GCI Summit - David Feifel - University of California, San Diego - Kadima Neuropsychiatry Institute - GCI Virtual Summit - Global Cannabis Intelligence

GCI Virtual Summit Thought Leader – Dr. David Feifel, Kadima Neuropsychiatry Institute

David participated as a thought leader at the GCI Virtual Summit 2020, joining 1000+ registered global leaders in both cannabis and psychedelics.

Check out his bio below:

Dr. David Feifel is Professor Emeritus at University of California, San Diego and a pioneer in treating mental illness with innovative approaches such as neuromodulation and psychedelics. In addition to board certification in general psychiatry, he has received subspecialty certification in Psychosomatic Medicine, and in Behavioral Neurology and Neuropsychiatry.

He has published more than 120 peer-reviewed research papers and his work has been featured the New York Times, Time magazine, NPR, The Washington Post, Scientific America, and Stern, among others.

In 2008, while at UCSD, he established the first clinical program in the world to offer ketamine infusions for psychiatric disorders. Among his distinctions is membership in the American College of Neuropharmacology, and being listed in ‘Best Doctors in America’, and Castle Connelly’s ‘Top Doctors’.  He has received research funding from the National Association for Research in Schizophrenia and Depression (NARSAD), the Scottish Rite Organization, the Stanley Medical Research Institute, Kavli Institute for Brain and Mind and the National Institute of Mental Health.

He is currently President of Kadima Neuropsychiatry Institute, a private institute in La Jolla, California, focusing on providing advance treatments such as Deep Transcranial Magnetic Stimulation, ketamine, and other psychedelic compounds. At Kadima he also oversees research to improve these treatments and develop novel ones, often in collaboration with other parties working in this space. Among the ongoing projects at Kadima are clinical trials of psilocybin for psychiatric disorders sponsored by Compass Pathways LTD.

If you are a leader operating in either the cannabis or psychedelics industries, check out the GCI Virtual Summit today! You can submit an application for a complimentary ticket for our 2021 Summit here.

You can also check out exclusive interviews with some of our GCI Virtual Summit thought leaders on the Content Hub.